title: A revised age for the Kawakawa/Oruanui tephra, a key marker for the Last Glacial Maximum in New Zealand

authors: Vandergoes, Marcus J.

abstract: The Kawakawa/Oruanui tephra (KOT) is a key chronostratigraphic marker in terrestrial and marine deposits of the New Zealand (NZ) sector of the southwest Pacific. Erupted early during the Last Glacial Maximum (LGM), the wide distribution of the KOT enables inter-regional alignment of proxy records and facilitates comparison between NZ climatic variations and those from well-dated records elsewhere. We present 22 new radiocarbon ages for the KOT from sites and materials considered optimal for dating, and apply Bayesian statistical methods via OxCal4.1.7 that incorporate stratigraphic information to develop a new age probability model for KOT. The revised calibrated age, ±2 standard deviations, for the eruption of the KOT is 25,360 ± 160 cal yr BP. The age revision provides a basis for refining marine reservoir ages for the LGM in the southwest Pacific.

text: A revised age for the Kawakawa/Oruanui tephra, a key marker for the Last Glacial Maximum in New Zealand The Kawakawa/Oruanui tephra (KOT) is a key chronostratigraphic marker in terrestrial and marine deposits of the New Zealand (NZ) sector of the southwest Pacific. Erupted early during the Last Glacial Maximum (LGM), the wide distribution of the KOT enables inter-regional alignment of proxy records and facilitates comparison between NZ climatic variations and those from well-dated records elsewhere. We present 22 new radiocarbon ages for the KOT from sites and materials considered optimal for dating, and apply Bayesian statistical methods via OxCal4.1.7 that incorporate stratigraphic information to develop a new age probability model for KOT. The revised calibrated age, ±2 standard deviations, for the eruption of the KOT is 25,360 ± 160 cal yr BP. The age revision provides a basis for refining marine reservoir ages for the LGM in the southwest Pacific.

year: 2013

title: Exploring Pacific picturebooks to support the language, culture and identity of Pasifika children. A summer scholar’s perspective

authors: Kelly-Ware, Janette Patricia

abstract: Populations of Pacific People in Aotearoa New Zealand are growing, and many education documents recognise the need to support the language, culture and identity of children from these communities in educational settings.
In this article we explore the potental of picturebooks to support principles from Te Whāriki and Tapasā. Specifically we report on the findings of a Summer Scholarship research project at The University of Waikato where a Summer Scholar (Cushla Foe) identified 90 picturebooks featuring Pacific Peoples published since 2013. We present content analysis of one picturebook in terms of how Samoan language and identity are reflected in the text and illustration, and how this links to principles and Turu competencies in Te Whāriki (MoE, 2017) and Tapasā (MoE, 2018).

text: Exploring Pacific picturebooks to support the language, culture and identity of Pasifika children. A summer scholar’s perspective Populations of Pacific People in Aotearoa New Zealand are growing, and many education documents recognise the need to support the language, culture and identity of children from these communities in educational settings.
In this article we explore the potental of picturebooks to support principles from Te Whāriki and Tapasā. Specifically we report on the findings of a Summer Scholarship research project at The University of Waikato where a Summer Scholar (Cushla Foe) identified 90 picturebooks featuring Pacific Peoples published since 2013. We present content analysis of one picturebook in terms of how Samoan language and identity are reflected in the text and illustration, and how this links to principles and Turu competencies in Te Whāriki (MoE, 2017) and Tapasā (MoE, 2018).

year: 2021

title: Characteristics and outcomes of patients with small cell lung cancer - findings from a New Zealand SACT database

authors: Lawrenson, Ross

abstract: Background Small Cell Lung Cancer (SCLC) SCLC generally presents late and is treated with systemic anti-cancer treatment (SACT). Māori are over represented in Lung Cancer statistics but disparities between Māori and non-Māori in patterns of care and survival from SCLC have not been previously reported. 
Methods We used the custom-built SACT database collected by the Oncology Department at Waikato Hospital NZ, which recorded comprehensive lung cancer patient factors and SACT regimens from 2000 to 2021. We reported summary statistics to review the treatment by ethnicity, explored Kaplan Meier all-cause survival of patients, and estimated the unadjusted and adjusted odds ratios of surviving 12 months. 
Results 742 patients with SCLC were included in this study, with 43% identified as Māori. Approximately 75% of patients received SACT, and there was no difference in the uptake of SACT between Māori and non-Māori. The median survival for SCLC was 8.5 months. After adjustment, patients treated with carboplatin plus etoposide (with/without durvalumab) or cisplatin plus etoposide were 1.5 times or 4.9 times respectively more likely to survive 12 months than those without a SACT regimen.
Conclusion There was no significant evidence of disparities in patterns of care and outcomes between Māori and non-Māori with SCLC. Carboplatin/cisplatin in combination with etoposide remained the primary first line SACT regimen for patients with SCLC in this New Zealand cancer treatment centre.

text: Characteristics and outcomes of patients with small cell lung cancer - findings from a New Zealand SACT database Background Small Cell Lung Cancer (SCLC) SCLC generally presents late and is treated with systemic anti-cancer treatment (SACT). Māori are over represented in Lung Cancer statistics but disparities between Māori and non-Māori in patterns of care and survival from SCLC have not been previously reported. 
Methods We used the custom-built SACT database collected by the Oncology Department at Waikato Hospital NZ, which recorded comprehensive lung cancer patient factors and SACT regimens from 2000 to 2021. We reported summary statistics to review the treatment by ethnicity, explored Kaplan Meier all-cause survival of patients, and estimated the unadjusted and adjusted odds ratios of surviving 12 months. 
Results 742 patients with SCLC were included in this study, with 43% identified as Māori. Approximately 75% of patients received SACT, and there was no difference in the uptake of SACT between Māori and non-Māori. The median survival for SCLC was 8.5 months. After adjustment, patients treated with carboplatin plus etoposide (with/without durvalumab) or cisplatin plus etoposide were 1.5 times or 4.9 times respectively more likely to survive 12 months than those without a SACT regimen.
Conclusion There was no significant evidence of disparities in patterns of care and outcomes between Māori and non-Māori with SCLC. Carboplatin/cisplatin in combination with etoposide remained the primary first line SACT regimen for patients with SCLC in this New Zealand cancer treatment centre.

year: 2023-02-10